Current Oncology Reports

, Volume 13, Issue 3, pp 186–194 | Cite as

Hepatocellular Carcinoma: Prevention and Therapy

  • Davendra P. S. Sohal
  • Weijing Sun


Hepatocellular carcinoma (HCC) is an aggressive malignancy of the liver and occurs most often in the setting of chronic liver disease. The most common acquired causes for this are chronic viral hepatitis infections (mostly HBV and HCV), and alcohol. Other causes include nonalcoholic fatty liver disease–related nonalcoholic steatohepatitis, autoimmune liver disease, and biliary diseases. In addition, certain heritable diseases like hemochromatosis and α-1-antitrypsin deficiency can also lead to HCC. Therefore, prevention of HCC can be achieved by preventing and controlling these problems. For treatment, curative modalities are surgical resection and liver transplantation. However, most patients are not candidates for these surgical maneuvers, and outcomes are poor. New therapeutic developments have brought some improvement with both local and systemic disease control.


Hepatocellular carcinoma (HCC) Hepatitis B virus (HBV) Hepatitis C virus (HCV) Nonalcoholic steatohepatitis (NASH) Cirrhosis Prevention Vaccine Resection Transplantation Ablation Transarterial chemoembolization (TACE) Chemotherapy Sorafenib 



No potential conflicts of interest relevant to this article were reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis. 2007;11:191–207. x-xi.PubMedCrossRefGoogle Scholar
  4. 4.
    Kudo M. Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology;78 Suppl 1:1–6.Google Scholar
  5. 5.
    Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett. 2009;286:15–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Chang MH, Shau WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000;284:3040–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat;17:435–43.Google Scholar
  8. 8.
    Sherman M. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med. 2009;76 Suppl 3:S6–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–S103.PubMedCrossRefGoogle Scholar
  12. 12.
    Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127:S79–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am. 2005;89:391–409.PubMedCrossRefGoogle Scholar
  14. 14.
    • AASLD Practice Guideline. Management of Hepatocellular Carcinoma: An Update. American Association for the Study of Liver Diseases., 2010. (Accessed October 31, 2010. at Updated guidelines on HCC management, by the American Association for Study of Liver Diseases.
  15. 15.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.PubMedGoogle Scholar
  16. 16.
    Ribero D, Curley SA, Imamura H, et al. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol. 2008;15:986–92.PubMedCrossRefGoogle Scholar
  17. 17.
    • Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol;21 Suppl 5:v59-64. Updated guidelines on HCC management, by the European Society for Medical Oncology. Google Scholar
  18. 18.
    Jaeck D, Bachellier P, Oussoultzoglou E, Weber JC, Wolf P. Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl. 2004;10:S58–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  21. 21.
    • Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009;9:31. Meta-analysis showing that RFA is better than ethanol injection as local therapy for HCC; although individual studies are somewhat heterogeneous, better survival was seen with RFA. PubMedCrossRefGoogle Scholar
  22. 22.
    Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer. 1995;76:1737–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009;249:195–202.PubMedCrossRefGoogle Scholar
  25. 25.
    Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Yao FY, Kerlan Jr RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48:819–27.PubMedCrossRefGoogle Scholar
  27. 27.
    Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol;33:41–52.Google Scholar
  28. 28.
    Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology;52:762–73.Google Scholar
  29. 29.
    Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.PubMedCrossRefGoogle Scholar
  30. 30.
    Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology;138:52–64.Google Scholar
  31. 31.
    • Benson AB, 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350–91. Updated guidelines on HCC management, by the National Comprehensive Cancer Network. Chemotherapy is not recommended outside of a clinical trial. PubMedGoogle Scholar
  32. 32.
    Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother;11:1943–55.Google Scholar
  33. 33.
    •• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90. This is the landmark randomized controlled trial of sorafenib versus placebo, showing an improvement in overall survival with sorafenib in advanced HCC. PubMedCrossRefGoogle Scholar
  34. 34.
    •• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. This is the second randomized controlled trial of sorafenib versus placebo showing an improvement in overall survival with sorafenib in advanced HCC. Conducted in a different geographic area, results were not as striking as in the SHARP trial, however. PubMedCrossRefGoogle Scholar
  35. 35.
    Cantarini MC, Trevisani F, Morselli-Labate AM, et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:91–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109:1384–90.PubMedCrossRefGoogle Scholar
  39. 39.
    • Qin S, Bai, Y., Ye, S., et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 2010;28:abstr 4008. Interesting preliminary results were seen in this randomized controlled trial: an improvement in overall survival with combination chemotherapy for advanced HCC. Final results are eagerly awaited. Google Scholar
  40. 40.
    Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03–03 trial. Br J Cancer. 2007;97:862–7.PubMedGoogle Scholar
  41. 41.
    Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112:2733–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898–903.PubMedCrossRefGoogle Scholar
  43. 43.
    Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102:981–6.Google Scholar
  44. 44.
    Sun W, Sohal D, Haller D, et al. Phase II Trial of Bevacizumab, Capecitabine and Oxaliplatin in Treatment of Advanced Hepatocellular Carcinoma. CA Cancer J Clin 2010.Google Scholar
  45. 45.
    Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843–50.PubMedCrossRefGoogle Scholar
  46. 46.
    Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma: A Randomized Trial. JAMA. 2010;304:2154–60.Google Scholar
  47. 47.
    • Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol;28:3994–4005. This report highlights the current practice standards for HCC treatment and outlines the major research questions that need to be answered, along with information on ongoing clinical trials that are addressing some of these questions. Google Scholar
  48. 48.
    Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 1998;133:183–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44:891–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Soderdahl G, Backman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int. 2006;19:288–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Medicine, Hematology and Oncology, Abramson Cancer CenterUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations